Mortality With Use of Paclitaxel-Eluting Stents Is Not Associated With Treatment Length or Drug Dosage: A Five-Year Real-World Experience

Abstract

The results of a study-level meta-analysis suggested an increase in late all-cause mortality with use of paclitaxel-coated devices in femoropopliteal endovascular interventions. Subsequent review of long-term clinical trial and patient-level data has reported no mortality difference between paclitaxel-coated and uncoated devices. We have reported our real-world experience of clinical efficacy and mortality with the use of paclitaxel-eluting stents.